瑞卢戈利联合治疗对子宫肌瘤患者生活质量的影响:LIBERTY随机试验
LIBERTY 1和LIBERTY 2两项多国双盲安慰剂对照3期试验共纳入509例有子宫肌瘤相关月经过多的绝经前女性,评估口服瑞卢戈利联合治疗(瑞卢戈利40mg+雌二醇1mg+醋酸炔诺酮0.5mg每日一次)对症状负担和生活质量的影响。24周时,联合治疗组在症状严重度、出血和盆腔不适、健康相关生活质量总分上均较安慰剂组显著改善。
要点
- 瑞卢戈利联合治疗24周显著降低子宫肌瘤症状严重度(-33.5 vs -12.1,名义P<.0001)。
- 出血和盆腔不适子量表改善显著(-48.4 vs -17.4,名义P<.0001)。
- 健康相关生活质量总分显著提高(+37.6 vs +13.1,名义P<.0001)。
核心结论
- 瑞卢戈利联合治疗24周后,有症状子宫肌瘤女性的健康相关生活质量各子量表均改善,包括情绪健康、身体和社交活动及性功能,关键肌瘤相关症状的总体负担和困扰也大幅降低。
研究设计与样本
- 两项重复、多国、双盲、24周、随机、安慰剂对照的3期研究LIBERTY 1和LIBERTY 2,纳入有子宫肌瘤相关月经过多(每周期≥80 mL持续2个周期或1个周期≥160 mL)的绝经前女性,共509例随机分组(2017年4月至2018年12月),本分析为汇总数据的二次分析。
主要发现
- 从基线至第24周,瑞卢戈利联合治疗组症状严重度降低-33.5,安慰剂组降低-12.1(名义P<.0001)。
- 出血和盆腔不适子量表评分瑞卢戈利联合治疗组降低-48.4,安慰剂组降低-17.4(名义P<.0001)。
- 健康相关生活质量总分瑞卢戈利联合治疗组提高+37.6,安慰剂组提高+13.1(名义P<.0001)。
- 应答分析显示,瑞卢戈利联合治疗组报告出血和盆腔不适子量表及身体和社交活动子量表达到临床意义改善的女性比例高于安慰剂组(名义P<.0001)。
关键数值与推荐
- 口服瑞卢戈利联合治疗方案为瑞卢戈利40 mg、雌二醇1 mg和醋酸炔诺酮0.5 mg每日一次。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Symptomatic uterine fibroids are burdensome to live with; they are associated with symptom-related distress, affect daily activities, and reduce health-related quality of life. The LIBERTY randomized clinical trials showed that oral relugolix combination therapy (40 mg relugolix, 1 mg estradiol, and 0.5 mg norethindrone acetate once daily) markedly improved fibroid-associated symptoms and conditions, including heavy menstrual bleeding, pain, and anemia, and was well-tolerated. OBJECTIVE: This study aimed to evaluate the effect of relugolix combination therapy on the symptom burden and health-related quality of life among women with uterine fibroids. STUDY DESIGN: Two replicate, multinational, double-blind, 24-week, randomized, placebo-controlled, phase 3 studies, LIBERTY 1 and LIBERTY 2, were conducted in premenopausal women with uterine fibroid-associated heavy menstrual bleeding (≥80 mL per cycle for 2 cycles or ≥160 mL during 1 cycle). The symptom burden and health-related quality of life were secondary endpoints and were assessed using the validated Uterine Fibroid Symptom and Quality of Life questionnaire, which the participants completed at baseline and at week 12 and 24 of treatment. For this secondary analysis, the pooled LIBERTY 1 and LIBERTY 2 data set was used. The Uterine Fibroid Symptom and Quality of Life questionnaire is made up of a Symptom Severity scale and a Health-Related Quality of Life scale, the latter of which includes 6 subscales focusing on the following aspects of daily life: concern, activities, energy or mood, control, self-consciousness, and sexual function. The Revised Activities subscale of the Health-Related Quality of Life scale addresses the impact of uterine fibroids on physical and social activities. Symptom burden was also assessed via the Bleeding and Pelvic Discomfort subscale, a patient-reported outcome measure derived from the Uterine Fibroid Symptom Severity scale that focuses on distress from key uterine fibroid symptoms, which was a key secondary endpoint. Least squares mean changes from baseline to week 24 in the Symptom Severity scale, Bleeding and Pelvic Discomfort subscale, overall Health-Related Quality of Life scale, and the respective subscales were compared between the relugolix combination therapy and placebo groups. Responder analyses of the proportion of women who experienced a clinically meaningful change from baseline to week 24 were conducted for the Bleeding and Pelvic Discomfort and the activity subscales. A stratified Cochran-Mantel-Haenszel test, adjusted for stratification factors (region [North America vs rest of world] and baseline menstrual blood loss volume), was used for treatment comparisons. RESULTS: Across both trials, 509 women were randomized to the relugolix combination therapy or placebo groups (April 2017-December 2018). Participants on relugolix combination therapy showed a statistically significant reduction in symptom severity (-33.5 vs -12.1; nominal P<.0001) and the Bleeding and Pelvic Discomfort subscale from baseline to week 24 when compared with those on placebo treatment (-48.4 vs -17.4; nominal P<.0001). Overall, the total Health-Related Quality of Life scores improved significantly from baseline to week 24 in the relugolix combination therapy group when compared with the placebo (+37.6 vs +13.1; nominal P<.0001). Responder analyses demonstrated that more women treated with relugolix combination therapy reported a clinically meaningful reduction in the Bleeding and Pelvic Discomfort subscale and an improvement in physical and social activities when compared with those treated with the placebo (nominal P<.0001). CONCLUSION: After 24 weeks of treatment with relugolix combination therapy, women with symptomatic uterine fibroids experienced substantial improvements in health-related quality of life with all subscales showing improvement, including emotional well-being, physical and social activities, and sexual function. In addition, women reported substantial reductions in the overall symptom burden and distress caused by key fibroid-associated symptoms.
引用
- Stewart EA, Lukes AS, Venturella R, et al. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol. 2022. PMID: 36370871. doi:10.1016/j.ajog.2022.11.1278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。